Search

Your search keyword '"Camille Vatier"' showing total 108 results

Search Constraints

Start Over You searched for: Author "Camille Vatier" Remove constraint Author: "Camille Vatier" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
108 results on '"Camille Vatier"'

Search Results

1. Diagnostic and referral pathways in patients with rare lipodystrophy and insulin-resistance syndromes: key milestones assessed from a national reference center

2. A Family with a Single LMNA Mutation Illustrates Diversity in Cardiac Phenotypes Associated with Laminopathic Progeroid Syndromes

4. European lipodystrophy registry: background and structure

5. Molecular and Cellular Bases of Lipodystrophy Syndromes

6. Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes

7. Looking at New Unexpected Disease Targets in LMNA-Linked Lipodystrophies in the Light of Complex Cardiovascular Phenotypes: Implications for Clinical Practice

8. Glyceroneogenesis is inhibited through HIV protease inhibitor-induced inflammation in human subcutaneous but not visceral adipose tissue

9. Correction: A Dietary Supplement Containing Cinnamon, Chromium and Carnosine Decreases Fasting Plasma Glucose and Increases Lean Mass in Overweight or Obese Pre-Diabetic Subjects: A Randomized, Placebo-Controlled Trial.

10. A Dietary Supplement Containing Cinnamon, Chromium and Carnosine Decreases Fasting Plasma Glucose and Increases Lean Mass in Overweight or Obese Pre-Diabetic Subjects: A Randomized, Placebo-Controlled Trial.

11. Perinatal, metabolic, and reproductive features inPPARG-related lipodystrophy

12. Role of insulin resistance on fertility – Focus on polycystic ovary syndrome

13. Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real‐life experience from a national reference network

14. Identification of predictive criteria for pathogenic variants of primary bilateral macronodular adrenal hyperplasia (PBMAH) gene ARMC5 in 352 unselected patients

15. Proceedings of the annual meeting of the European Consortium of Lipodystrophies (ECLip) Cambridge, UK, 7-8 April 2022

16. Lessons from the impact of COVID-19 on medical educational continuity and practices

17. Lipodystrophies induites par les glucocorticoïdes : de la physiopathologie à la prise en charge

18. Lipodystrophies génétiques partielles, de la physiopathologie à la prise en charge

19. The adiponectin to leptin ratio, a still unrecognized biomarker of insulin resistance and cardiometabolic risk

20. Impact of diabetes on COVID-19 prognosis beyond comorbidity burden: the CORONADO initiative

21. Author response for 'Influenza vaccination and prognosis of COVID ‐19 in hospitalized patients with diabetes: Results from the CORONADO study'

22. Reply to Morje et al

23. Monitoring gestational diabetes mellitus patients with the telemedicine application MyDiabby decreases the rate of foetal macrosomia

24. [Mutltifaceted biological roles of leptin]

25. Rôles biologiques à multiples facettes de l’adiponectine

26. Cardiovascular complications of lipodystrophic syndromes – focus on laminopathies

27. Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies

28. Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study

29. Indications thérapeutiques et effets métaboliques de la métréleptine chez les patients atteints de lipodystrophie : données de vie réelle du registre français

30. Impact of pathogenic PPARG variants on pregnancy outcomes and in utero development

31. LIPE-related lipodystrophic syndrome: clinical features and disease modeling using adipose stem cells

32. Collaborateurs

33. Author response for 'Use of Dipeptidyl Peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: a propensity score analysis from the CORONADO study'

34. Author response for 'Relationship between obesity and severe <scp>COVID</scp> ‐19 outcomes in patients with type 2 diabetes: results from the <scp>CORONADO</scp> study'

35. Added value of buccal cell FISH analysis in the diagnosis and management of Turner syndrome

36. Blood glucose levels and COVID-19. Reply to Sardu C, D’Onofrio N, Balestrieri ML et al [letter] and Lepper PM, Bals R, Jüni P et al [letter]

37. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study

38. Correction to: Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study

39. Looking at New Unexpected Disease Targets in LMNA-Linked Lipodystrophies in the Light of Complex Cardiovascular Phenotypes: Implications for Clinical Practice

40. European lipodystrophy registry: background and structure

41. Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19

42. Relationship between obesity and severe COVID ‐19 outcomes in patients with type 2 diabetes: Results from the CORONADO study

43. Diagnostic Challenge in PLIN1-Associated Familial Partial Lipodystrophy

44. Severe Congenital Adrenal Hyperplasia Presenting as Bilateral Testicular Tumors and Azoospermia in the Third Decade of Life

45. Lipodystrophic syndromes due toLMNAmutations: recent developments on biomolecular aspects, pathophysiological hypotheses and therapeutic perspectives

46. LMNA-associated partial lipodystrophy: anticipation of metabolic complications

47. Impact des estrogènes sur la glycorégulation

48. Lipodystrophic syndromes: From diagnosis to treatment

49. Real-world experience of generalized and partial lipodystrophy patients enrolled in the metreleptin early access program

50. SUN-037 Diagnosis Challenge in Type 4 Familial Partial Lipodystrophic Syndrome

Catalog

Books, media, physical & digital resources